YELIVA (ABC294640)

Study Name
YELIVA (ABC294640)
OVERVIEW – in layman’s terms
YELIVA® is a novel investigational drug in an oral pill formulation, being developed by RedHill Biopharma (NASDAQ: RDHL). Several laboratory and animal studies as well as a Phase I clinical trial have been conducted with YELIVA®, suggesting potential effectiveness in cancer, including cholangiocarcinoma.
The most common drug-related side effects in the Phase I study with YELIVA® were nausea, vomiting and fatigue, all of which were mild to moderate.YELIVA® selectively inhibits SK2. By inhibiting SK2, YELIVA® inhibits the formation of sphingosine-1 phosphate (S1P), a molecule which promotes cancer growth as well as harmful immune reactions in certain diseases.YELIVA® is being studied in several clinical studies in various cancer types, including a Phase II study in patients with cholangiocarcinoma, which is planned to start later in 2017.
Recruitment starting in the fourth quarter of 2017
Purpose of the Study – in Layman’s Terms
  • Evaluate safety, tolerability and preliminary effectiveness of YELIVA® in patients with advanced, unresectable, intrahepatic, perihilar and extrahepatic cholangiocarcinoma
POTENTIAL SIDE-EFFECTS – in layman’s terms
  • nausea, vomiting and fatigue
Translate »

Pin It on Pinterest